Our conjugation technology and conjugation process know-how enable us to manufacture a wide range of conjugate vaccines. In addition to commonly used DT and TT carrier proteins, we have a number of carrier proteins including CRM197, which is produced by our proprietary high-yield bacterial strain and used in our MCV candidates. Our wide range of carrier proteins allows us to develop better multi-valent conjugate and combination vaccines, which distinguishes us from many of our competitors in China. In particular, our potential China best-in-class PCV13i employs a combination of different carrier proteins and is currently ready for CTA.
Copyright © ( 2017) CanSino Biologics Inc
For the record: 津ICP备14006666号-2